Seraphina Therapeutics
Seraphina Therapeutics is a San Diego-based health company that commercializes C15:0 (pentadecanoic acid) — the first essential fatty acid discovered in over 90 years — under its fatty15 brand, selling C15:0 supplements direct-to-consumer and through healthcare practitioners via Fullscript.
- Company typePrivate
- Founded2021
- HeadquartersSan Diego, United States
- Headcount1–10
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Seraphina Therapeutics does
Seraphina Therapeutics is a San Diego-based, privately held health and wellness company founded in 2017 (commercial launch January 2021) by husband-and-wife team Dr. Stephanie Venn-Watson (DVM, MPH, veterinary epidemiologist) and Dr. Eric Venn-Watson (MD, MBA, former Navy physician), together with co-founders Kim Kamdar (Managing Partner at Domain Associates, board chair) and Nicholas Schork (Senior Scientist; Distinguished Professor at Translational Genomics Institute / City of Hope). The company commercializes C15:0 (pentadecanoic acid), an odd-chain saturated fatty acid it characterizes as the first essential fatty acid discovered in over 90 years. The underlying IP originated in Dr. Venn-Watson's 20+ years of U.S. Navy research on bottlenose dolphins in San Diego; Seraphina holds exclusive global licensing rights from the U.S. Navy (U.S. Patent No. 11,116,740) for C15:0 as a supplement, food/beverage ingredient, and pharmaceutical, alongside 60+ granted and pending patents across metabolic, heart, liver, immune, brain, and healthy-aging indications.
The company's commercial product line is sold under the fatty15 brand: the original C15:0 dietary supplement distributed via a direct-to-consumer e-commerce subscription model (fatty15.com), and the practitioner-exclusive Fatty15 Advanced Formula Extra Strength launched in June 2026 through Fullscript, a platform serving 125,000+ healthcare practitioners and 5 million+ patients annually across North America. The D2C subscription business has scaled to 100,000+ active subscribers with a 95% monthly retention rate since launch, and the brand has earned 30+ industry awards (including the 2025 CNBC Changemaker for the CEO, Inc. 5000 fastest-growing supplement company in 2025, and multiple 2026 GHP, Mindful, and Beauty Shortlist accolades). The firm is backed by a single disclosed $5.5 million funding round (May 2020) led by Domain Associates with Murano Group, indicating a capital-efficient operating model. Scientific positioning is supported by 150+ peer-reviewed publications and a meta-analysis linking higher circulating C15:0 to a 32% lower risk of type 2 diabetes, with scientific advisors including Edward Dennis (UC San Diego) and Ronald Krauss (Harvard). The company has no disclosed AI/ML capabilities and its competitive advantage rests on patent exclusivity, clinical evidence, and founder credibility rather than data or machine-learning assets.
Seraphina Therapeutics firmographics
Firmographics- Name
- Seraphina Therapeutics
- Legal name
- Seraphina Therapeutics, Inc.
- Website
- https://seraphinatherapeutics.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Seraphina Therapeutics is a San Diego-based health company that commercializes C15:0 (pentadecanoic acid) — the first essential fatty acid discovered in over 90 years — under its fatty15 brand, selling C15:0 supplements direct-to-consumer and through healthcare practitioners via Fullscript.
- Ownership category
- akta.pro rank
Seraphina Therapeutics industry classification
Industry- Product category
- Dietary Supplements
- NAICS
- Food (Health) Supplement Retailers (456191)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Healthy Aging & Cognitive Support Supplements (CRADAGAM)
- akta.pro secondary industry
- Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity) (CRADAGAE)
Keywords
Where Seraphina Therapeutics is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Markets served
Seraphina Therapeutics business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Operations
Revenue model
- C15:0 Supplement Sales (Direct-to-Consumer): Seraphina Therapeutics generates revenue through direct-to-consumer sales of its fatty15 C15:0 supplement brand via e-commerce. The company has built a subscription-based model with over 100,000 active subscribers and a 95% monthly retention rate since January 2021 launch.
- Practitioner-Exclusive Supplement Sales: Revenue from selling the higher-dose Fatty15 Advanced Formula Extra Strength exclusively to healthcare practitioners through the Fullscript platform, serving over 125,000 practitioners and 5 million patients annually.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels3 records
Seraphina Therapeutics product offering
Product offeringCore offering
Seraphina Therapeutics develops and sells C15:0 (pentadecanoic acid) dietary supplements under the fatty15 brand for healthy aging and cellular health. Its core consumer product, the fatty15 C15:0 supplement, is sold via subscription through the company's direct-to-consumer e-commerce site, while a higher-dose practitioner-exclusive variant, Fatty15 Advanced Formula Extra Strength, is distributed exclusively through the Fullscript platform to healthcare practitioners who recommend it to patients. Both products are backed by 150+ peer-reviewed studies and an exclusive global licensing arrangement for C15:0 from the U.S. Navy and the United States of America.
Product overview
Seraphina Therapeutics is a health and wellness company that developed C15:0 (pentadecanoic acid) supplements based on research initially conducted studying U.S. Navy dolphins. The company offers two products: Fatty15, the core consumer supplement brand and the first essential fatty acid supplement in over 90 years; and Fatty15 Advanced Formula Extra Strength, a higher-dose practitioner-exclusive variant distributed through the Fullscript platform. Both products are backed by peer-reviewed research supporting healthy aging benefits.
Differentiator
Problem solved
Functional benefit
Brands
- fatty15: Primary C15:0 supplement brand launched in January 2021, offering essential fatty acid supplements for healthy aging. Includes original formula and Advanced Formula Extra Strength for practitioners.
Products and services
- Fatty15 C15:0 Supplement The flagship fatty15 C15:0 (pentadecanoic acid) dietary supplement sold directly to consumers via the fatty15.com e-commerce platform on a subscription basis, supporting cellular health, metabolic health, and healthy aging. Over 100,000 active subscribers with a 95% monthly retention rate since launch.
- Fatty15 Advanced Formula Extra Strength A higher-dose practitioner-exclusive C15:0 supplement available exclusively through the Fullscript platform for healthcare practitioners (doctors, naturopaths, health coaches) to recommend to their patients for metabolic, liver, cardiovascular, and inflammatory conditions.
Quantifiable outcome
- 32% lower risk of type 2 diabetes per 0.1% increase in C15:0 levels (meta-analysis in Advances in Nutrition)
- +3 more outcomes
Companies that use Seraphina Therapeutics
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
Seraphina Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
Seraphina Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- FullscriptcoreSeraphina Therapeutics partnered with Fullscript to make Fatty15 Advanced Formula Extra Strength available exclusively to healthcare practitioners. Fullscript is a platform trusted by over 125,000 healthcare practitioners serving more than 5 million patients annually across North America with supplements and clinical care tools.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
Seraphina Therapeutics competitors and assessment
Company assessmentDirect peers
- Elysium Health: Direct peer: science-backed DTC longevity supplement brand built around a single proprietary molecule (NAD+ precursor, Basis) with strong IP and clinical credibility. Closest 1:1 analog to Seraphina's C15:0 / fatty15 model.
- Thorne HealthTech: Science-driven supplement brand selling practitioner-grade and DTC products across multiple categories including healthy aging and metabolic health. Comparable subscription-based DTC model with practitioner channel.
- AG1 (Athletic Greens): Iconic DTC supplement subscription brand with very high retention and lifestyle positioning. Comparable growth trajectory, subscription model, and consumer health messaging.
- Ritual: Premium DTC supplement brand with subscription model, science-forward branding, and category-spanning product line. Similar brand positioning and consumer demographics to fatty15.
- Designs for Health: Practitioner-exclusive supplement brand with broad product portfolio including metabolic, cardiovascular, and liver support formulations. Comparable to Fatty15's Fullscript practitioner channel play.
- Life Extension: Long-established science-based supplement brand with strong longevity and cardiometabolic positioning. Comparable consumer demographic and direct-to-consumer supplement portfolio.
- Pure Encapsulations: NutriDyn/Pure Encapsulations is a practitioner-grade supplement brand with strong metabolic and cardiovascular health positioning. Overlaps directly with Fatty15 Advanced Formula's practitioner channel.
Emerging players
- Momentous: Emerging premium supplement brand with science-first positioning and longevity-adjacent products. Compares on brand narrative and DTC execution, though smaller practitioner footprint.
- Seed Health: Microbiome-focused DTC supplement brand with a subscription model and science-forward branding. Comparable consumer demographic and DTC mechanics, though differentiated category focus.
Broad incumbents
- Nestlé Health Science: Broad incumbent in medical nutrition, supplements, and longevity nutrition. Relevant as a potential acquirer or partner, and as a scaled competitor with deeper distribution into pharmacy and clinical channels.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Seraphina Therapeutics social profiles
Digital presenceSeraphina Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Seraphina Therapeutics leadership team
Management profileNumber of profiles
Profiles6 records
Seraphina Therapeutics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Seraphina Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Seraphina Therapeutics
What does Seraphina Therapeutics do?
Seraphina Therapeutics develops and sells C15:0 (pentadecanoic acid) dietary supplements under the fatty15 brand for healthy aging and cellular health. Its core consumer product, the fatty15 C15:0 supplement, is sold via subscription through the company's direct-to-consumer e-commerce site, while a higher-dose practitioner-exclusive variant, Fatty15 Advanced Formula Extra Strength, is distributed exclusively through the Fullscript platform to healthcare practitioners who recommend it to patients. Both products are backed by 150+ peer-reviewed studies and an exclusive global licensing arrangement for C15:0 from the U.S. Navy and the United States of America.
Is Seraphina Therapeutics a public or private company?
Seraphina Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Seraphina Therapeutics founded?
Seraphina Therapeutics was founded in 2021. It employs 1 to 10 people.
Where is Seraphina Therapeutics based?
Seraphina Therapeutics is headquartered in San Diego, United States, in the North America region.
How does Seraphina Therapeutics make money?
Two revenue lines are on record. C15:0 Supplement Sales (Direct-to-Consumer) is the primary driver. The others are practitioner-Exclusive Supplement Sales.
Who are Seraphina Therapeutics's main competitors?
Direct peers on record are Elysium Health, Thorne HealthTech, AG1 (Athletic Greens), Ritual, Designs for Health, Life Extension and Pure Encapsulations. Emerging players are Momentous and Seed Health. Nestlé Health Science is listed as a broad incumbent.
Does Seraphina Therapeutics have an API?
No public API is recorded for Seraphina Therapeutics.
What industry is Seraphina Therapeutics in?
Seraphina Therapeutics's product category is Dietary Supplements. Its primary akta.pro industry code is CRADAGAM, Healthy Aging & Cognitive Support Supplements, with a secondary code of CRADAGAE, Specialty Condition Supplements (Sleep, Stress, Heart, Joint, Gut, Immunity). Its NAICS code is 456191 and its SIC code is 2833.